NYSE:RCUS
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.'s revenue fell 4.3% in fiscal 2025 to $247.0M while operating margin fell to −156.3%. Free cash flow was −$484.0M, −196.0% of revenue, and the diluted share count rose 19.2%.Summary generated from Arcus Biosciences, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$247.0M
Revenue growth−4.3%
Revenue, 5-yr CAGR+25.9%
Gross marginn/a
Operating margin−156.3%
Net margin−142.9%
ROIC−68.4%
Return on equity−63.3%
Debt / equity0.16
Free cash flow−$484.0M
FCF margin−196.0%
Share count change+19.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 383 | 112 | 117 | 258 | 247 |
| Operating income | 54 | −280 | −340 | −330 | −386 |
| Net income | 53 | −267 | −307 | −283 | −353 |
| Free cash flow | −282 | 432 | −330 | −176 | −484 |
Recent filings
- 4Insider transaction report
Aug 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 4Insider transaction report
Jul 13, 2026 - 8-KResults of a shareholder vote
Jun 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026 - 8-KResults of operations and financial condition
May 5, 2026 - DEF 14AProxy statement
Apr 21, 2026